Overview

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc.
Transition Therapeutics Ireland Limited
Collaborator:
Elan Pharmaceuticals
Treatments:
Anticonvulsants
Inositol
Lamotrigine
Valproic Acid